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In Drosophila S2 cells, the apical caspase DRONC
undergoes a low level of spontaneous autoprocessing.
Unintended apoptosis is prevented by the inhibitor of
apoptosis DIAP1, which targets the processed form of
DRONC for degradation through its E3 ubiquitin pro-
tein ligase activity. Recent reports have demonstrated
that shortly after the initiation of apoptosis in S2 cells,
DIAP1 is cleaved following aspartate residue Asp-20 by
the effector caspase DrICE. Here we report a novel
caspase-mediated cleavage of DIAP1 in S2 cells. In
both living and dying S2 cells, DIAP1 is cleaved by
DRONC after glutamate residue Glu-205, located be-
tween the first and second BIR domains. The mutation
of Glu-205 prevented the interaction of DIAP1 and pro-
cessed DRONC but had no effect on the interaction
with full-length DRONC. The mutation of Glu-205 also
had a negative effect on the ability of overexpressed
DIAP1 to prevent apoptosis stimulated by the proapo-
ptotic protein Reaper or by UV light. These results
expand our knowledge of the events that occur in the
Drosophila apoptosome prior to and after receiving an
apoptotic signal.
IAP1 proteins were first discovered in baculoviruses and
have now been found in a wide range of organisms (1). IAPs are
identified by the presence of at least one baculovirus IAP re-
peat (BIR), a roughly 70-amino acid domain shown to be im-
portant for protein-protein interactions. Many IAPs also con-
tain a C-terminal RING finger domain, and several of these
have been shown to possess E3 ubiquitin ligase activity (2–8).
Although all IAP proteins contain a BIR domain, not all
BIR-containing proteins can inhibit apoptosis, and some BIR-
containing proteins have been implicated in cell signaling and
cell cycle regulation (9). Several IAPs have been shown to
directly bind and inhibit the activity of a family of proapoptotic
proteins known as caspases (10, 11). Caspases are cysteine
proteases and are synthesized as zymogens, which must usu-
ally be proteolytically cleaved to become activated (12). They
are divided into two types depending on the size of an N-
terminal prodomain found on all caspases. Initiator caspases
are identified by a long prodomain, whereas a short prodomain
is indicative of an effector caspase. Upon reception of a death
signal, upstream initiator caspases are first activated and in
turn cleave and activate downstream effector caspases leading
to apoptosis.
In mammalian cells, caspase-9 functions as the initiator
caspase for the intrinsic death pathway and upon induction of
apoptosis associates with APAF-1, the mammalian CED-4
homolog. Caspase-9 and APAF-1 binding occur through their
mutual CARD domains and along with the cofactors cyto-
chrome c and dATP form the apoptosome. The apoptosome is a
large complex that induces dimerization and activation of
caspase-9 (13). Activated caspase-9 then activates effector
caspases including caspase-3 and caspase-7, which bring about
the morphological and biochemical events associated with apo-
ptosis. In mammalian cells, apoptosome formation is thought to
occur only after the cell has received an apoptotic signal.
In Drosophila, DREDD and DRONC have been identified as
initiator caspases and have been shown to interact with DARK,
the Drosophila APAF-1/CED-4 ortholog (14, 15). Studies have
shown that in unstimulated Drosophila BG2 cells DRONC is
found in a large molecular weight complex (16), and in normal
living Drosophila S2 cells, DRONC undergoes continuous auto-
processing via a DARK-dependent mechanism (17, 18). Other
cofactors such as cytochrome c do not seem to be necessary for
apoptosome formation in Drosophila (16, 19–21), although the
details of this process are not well understood. The Drosophila
DIAP1 protein is required for cell viability in the developing
embryo, as demonstrated by extensive apoptosis early in devel-
opment and embryonic lethality in a DIAP1 mutant fly (22). In
addition silencing of DIAP1 by RNAi in S2 cells causes spon-
taneous apoptosis, as does silencing of an iap gene in Sf21 cells,
a lepidopteran insect cell line (17, 20, 23). This result differs
from mammalian cells in which a knock-out mouse of a mam-
malian IAP, XIAP, was shown to be essentially normal, al-
though the levels of cIAP1 and cIAP2 were elevated suggesting
that they may have compensated for the absence of XIAP (24).
Thus, insect cells appear to differ frommammalian cells in that
apoptosome formation and apical caspase activation are always
occurring, and continuous IAP expression is required for
cell viability.
Certain IAPs have been determined to themselves be caspase
substrates, and during apoptosis XIAP and cIAP1 are cleaved
in a caspase-dependent manner. XIAP cleavage was observed
in Jurkat cells during Fas-induced apoptosis and resulted in
reduced levels of XIAP protein and progression of apoptosis
(25). Cleavage of cIAP1 also reduced protein levels and in
addition resulted in the production of a proapoptotic C-termi-
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nal fragment suggesting that in mammals caspase cleavage
reduces IAP levels and may also have other effects on IAP
function (26).
InDrosophila S2 cells, DIAP1 is also a caspase substrate and
is cleaved by the Drosophila effector caspase DrICE. Using
purified proteins Meier and co-workers (27) determined that
DIAP1 was cleaved by DrICE at position Asp-20. DrICE cleav-
age at amino acid Asp-20 of DIAP1 produces a processed form
that possesses an asparagine at the N terminus and is recog-
nized by the N-end rule degradation pathway. In agreement
with this hypothesis it was determined that mutations at
amino acid Asp-20 inhibited the degradation of DIAP1 when
expressed in cells. The mutation of Asp-20 also reduced the
ability of DIAP1 to inhibit apoptosis stimulated by overexpres-
sion of Reaper; however, effects on other death stimuli were not
reported (27). In addition, it has been shown that DrICE binds
BIR1 of DIAP1 and that cleavage of DIAP1 by DrICE at Asp-20
is required for DrICE binding and inhibition (28). However, a
more recent report concluded that DrICE cleavage of DIAP1 at
position Asp-20 was not important for the ability of DIAP1 to
inhibit apoptosis stimulated by overexpression of Reaper or
Hid (29).
In this study we observed a cleavage product of Drosophila
DIAP1 in Drosophila S2 cells that differed in size from the
DrICE-mediated cleavage product reported previously. This
cleavage product was unstable, because it was only seen in the
presence of a proteasome inhibitor. However, it was evident in
both normal and dying cells. Accumulation of the DIAP1 cleav-
age product was inhibited by the caspase inhibitor z-VAD-FMK
or by silencing of DRONC or DARK by RNAi. Using recombi-
nant proteins, we found that DRONC readily cleaved DIAP1 in
vitro, resulting in a digestion product similar in size to that
seen in cells. The DRONC cleavage site in DIAP1 was mapped
to amino acid Glu-205 in the spacer region separating BIR1
from BIR2 and the C-terminal RING domain. In vitro co-im-
munoprecipitations revealed that mutations at amino acid Glu-
205 inhibited binding of DIAP1 to processed DRONC but not to
full-length DRONC. In addition, when the Glu-205 mutant was
overexpressed in S2 cells, its ability to protect cells against
apoptosis induced by Reaper overexpression was reduced, sug-
gesting that cleavage of DIAP1 by DRONC is involved in apo-
ptosis regulation.
MATERIALS AND METHODS
Protein Purification—The vector expressing GST-DIAP1 was pro-
vided by Bruce Hay (Wang et al., Ref. 22). The mutant versions of
DIAP1 were generated using polymerase chain reaction and the
QuikChange site-directed mutagenesis kit (Stratagene). The DRONC
coding region was introduced into pET23(a) (Novagen) to produce
pDronc-His6 (C-terminally tagged). All DIAP1 and DRONC con-
structs were expressed in Escherichia coli BL21 (DE3) pLysS (Strat-
agene). For protein purification bacteria were grown at room temper-
ature to OD600 of 0.4 and were induced with 0.1 mM IPTG for 1 h at
room temperature. After induction bacteria were frozen overnight at
80 °C and then thawed in lysis buffer (200 mM Tris-HCl, pH 8.0, 0.4
M ammonia sulfate, 10 mM MgCl2, and 10% glycerol  proteasome
inhibitor mixture (Roche)). Bacteria were then sonicated on ice at
50% pulse for 3 min in 15-s intervals. The soluble and insoluble
fractions were separated by centrifugation at 12,000  g for 10 min.
The DIAP1 soluble fractions were purified using glutathione-Sepha-
rose beads (Sigma), and DRONC soluble fractions were purified using
cobalt Talon resin (Clontech) per manufacture’s instructions. Protein
concentrations were then determined by comparing purified proteins
to known concentrations of bovine serum albumin on a Coomassie
Blue-stained SDS-polyacrylamide gel.
DIAP1 Cleavage—For DRONC cleavage of DIAP1, 200 ng of wild
type GST-DIAP1 or the single and double mutants were mixed with
increasing concentrations (10–500 ng) of wild type DRONC-His in 30 l
of buffer A (25 mM Tris-HCl, pH 8.0, 50 mM NaCl, and 10 mM dithio-
threitol). The reaction mixtures were then incubated at 30 °C for 1 h.
After incubation the DIAP1 the reactions were stopped by adding SDS-
PAGE sample buffer and were then run on a 15% SDS-polyacrylamide
gel. DIAP1 protein was then detected by Western blot using an anti-
DIAP1 monoclonal antibody (obtained from Bruce Hay) at 1:3,500,
anti-mouse IgG-horseradish peroxidase antibody at 1:6,500, and Super-
signal West Pico Chemiluminescent Substrate (Pierce).
S2 Cell Viability—S2 cells were co-transfected with a plasmid
expressing enhanced green fluorescent protein (eGFP) under the
Drosophila heat shock promoter and either wild type DIAP1, N-
DIAP1 (205–438 DIAP1), C-DIAP1 (1–205 DIAP1), or the single
and double point mutants under the control of the constitutively
active baculovirus IE1 promoter. The complete sequences of all of the
mutant constructs were verified to ensure there were not any inad-
vertent mutations introduced during their construction. For Reaper
viability, cells were also transfected with a plasmid expressing
Reaper, and 48 h after transfection the number of viable green
fluorescent cells was determined by counting three fields of view
under 400 magnification. Control cells not receiving Reaper were
set at 100%. For UV light viability, 20 h after transfection cells were
UV light-irradiated by placing the plates on a transilluminator for 10
min. At 24 h after UV light treatment the number of viable green
fluorescent cells was counted, and the percentage of viable cells
remaining was determined by setting the number of green fluorescent
cells at 100% 1 h after UV light treatment. To detect the expressed
proteins, transfected cells were subjected to Western blotting using
anti-DIAP1 antibody as described above, except that less lysate was
used to better illustrate the difference in levels between endogenous
DIAP1 and the exogenously expressed DIAP1 proteins.
Co-immunoprecipitations—Using recombinant GST-DIAP1 and re-
combinant DRONC-His, 200 ng of each DIAP1 construct was added to
500 ng of wild type or catalytically inactive DRONC in 30 l of buffer A.
The reactions were added to protein G beads (Sigma), bound to anti-
DRONC antibody (obtained from Bruce Hay), and rocked overnight at
4 °C. The beads were then washed, and bound protein was eluted in
SDS-PAGE sample buffer. The eluted protein was run on a 12% SDS-
polyacrylamide gel, and DIAP1 protein was detected by Western blot
using anti-DIAP1 antibody at 1:1,000 and anti-mouse IgG-horseradish
peroxidase antibody at 1:10,000. For the co-immunoprecipitations of
endogenous protein, 6 million S2 cells were plated overnight and then
UV light-treated for 10 min. Cells were harvested at various times post
UV light and lysed in Nonidet P-40 buffer (50 mM Tris-HCl, pH 8.0, 150
mM NaCl, 1% Nonidet P-40, 1 mM dithiothreitol, and 1 mM phenylmeth-
ylsulfonyl fluoride). The incubation with anti-DRONC bound protein G
beads (Sigma) was performed as for recombinant protein. DIAP1 pro-
tein was then detected by Western blot using anti-DIAP1 antibody at
1:4,000 and anti-DRONC antibody at 1:7,000.
Conditions for RNAi in Drosophila Cell Culture—RNAi methods
were essentially as described (17, 30). In brief, S2 cells were plated
overnight at 6 million cells/well in 6-well plates in TC100 medium
(Invitrogen) containing 10% fetal bovine serum (Invitrogen). The cells
were then placed in TC100 medium without serum and dronc or dark
dsRNA was added directly to the medium to a final concentration of 40
g/ml followed by vigorous shaking. The cells were incubated for 5.5 h
at 25 °C at which time serum was added to a final concentration of 10%
serum. To allow time for protein turnover the cells were incubated for
24 h before proceeding with the rest of the experiment. We have previ-
ously shown this amount of time to be sufficient to significantly reduce
DRONC and DARK protein levels (17).
RESULTS
DIAP1 Protein Levels Are Regulated by Both the Proteasome
and Caspase Cleavage—Recent studies have found that the
Drosophila inhibitor of apoptosis protein, DIAP1, is short lived
and upon induction of apoptosis is rapidly removed (7, 31).
Using Drosophila S2 cells we confirmed that endogenous
DIAP1 protein levels were undetectable 3 h after UV light
treatment (Fig. 1A). Several IAPs, including DIAP1, have re-
cently been shown to possess E3 ubiquitin ligase activity and
induce the degradation of themselves and other apoptotic pro-
teins (5, 31). We therefore were interested in investigating the
effects of the proteasome inhibitor MG132 on the rate of DIAP1
degradation. MG132 treatment of UV light-irradiated cells de-
layed, but did not completely prevent, the degradation of
DIAP1 and also resulted in the appearance and accumulation
of a 27-kDa immunoreactive band (Fig. 1B). In addition,
MG132 treatment somewhat delayed the progression of apo-
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ptosis, which may have been because of the slower degradation
of full-length DIAP1 (data not shown). Because some mamma-
lian IAP proteins are cleaved by caspases (25, 26), we suspected
that the 27-kDa protein was the result of caspase cleavage. To
examine this, S2 cells were treated with the pan-caspase in-
hibitor z-VAD-FMK with or without MG132 prior to inducing
apoptosis. Interestingly, the 27-kDa band was not present
when cells were treated with z-VAD-FMK alone (Fig. 1C) or
with both z-VAD-FMK andMG132 (Fig. 1D). Moreover, z-VAD-
FMK treatment also caused a delay in the decrease in full-
length DIAP1 (Fig. 1C) indicating that the amount of full-
length DIAP1 is regulated by both proteasomal degradation
and caspase cleavage in apoptotic S2 cells.
DRONC Continuously Cleaves DIAP1—In normal, living
Drosophila S2 cells, DIAP1 is required to inhibit spontaneous
apoptosis (17, 20, 23). We therefore monitored DIAP1 protein
levels in non-apoptotic cells treated with MG132. DIAP1 West-
ern blots showed no over-accumulation of full-length DIAP1
following proteasome inhibition but rather showed an accumu-
lation of the 27-kDa fragment of DIAP1, which at times also
appeared to be modified in a manner consistent with ubiquiti-
nation (Fig. 2A). MG132 treatment itself had no effect on cell
viability (data not shown). These results suggested that DIAP1
is continuously cleaved in non-apoptotic S2 cells, possibly by
one or more caspases. The initiator caspase DRONC was a good
candidate for the caspase that cleaves DIAP1, because DIAP1
is known to bind and ubiquitinate DRONC (7), DRONC has
previously been shown to also be continuously processed and
degraded in normal S2 cells, and DIAP1 RNAi results in the
accumulation of processed DRONC (17, 18). To investigate
whether DRONC is required for cleavage of DIAP1 we used
RNAi to silence either DRONC or DARK, the APAF-1/CED-4
homolog that is required for DRONC activation. Twenty-four
hours after the addition of either dronc or dark dsRNA, S2 cells
were treated with MG132. Immunoblot analysis indicated that
silencing of either DRONC or DARK greatly reduced the accu-
mulation of the DIAP1 27-kDa fragment (Fig. 2B). To deter-
mine whether endogenous DRONC and DIAP1 interact in S2
cells, cells were UV light-irradiated, and at various times ly-
sates were immunoprecipitated using anti-DRONC antiserum.
Anti-DIAP1 Western blots of the immunoprecipitated samples
showed that in non-apoptotic cells, DRONC interacted with
both full-length DIAP1 and the 27-kDa cleavage fragment of
DIAP1, although the interaction with cleaved DIAP1 appeared
much stronger (Fig. 2C, lane 1). These results indicate that in
non-apoptotic cells, activated DRONC is necessary for DIAP1
cleavage and support our previous finding that a portion of the
DRONC protein in non-apoptotic cells is activated but is inhib-
ited prior to activating effector caspases (17).
DRONC Cleaves DIAP1 in the Spacer Region between BIR1
and BIR2—To further verify that DRONC was directly respon-
sible for DIAP1 cleavage, we examined the ability of DRONC to
cleave DIAP1 in reactions using recombinant, purified pro-
teins. When recombinant DIAP1 was incubated with increas-
ing concentrations of recombinant DRONC, DIAP1 was readily
cleaved, resulting in cleavage products of50 and 27 kDa (Fig.
3A). The recombinant DIAP1 protein used in this experiment
was fused with glutathione S-transferase (GST) at the N ter-
minus, and an anti-GST immunoblot showed that the 50-kDa
cleavage product included the N terminus of DIAP1 (data not
shown). We therefore concluded that the 27-kDa fragment,
which was similar to the cleavage product seen in S2 cells,
represented the C-terminal portion of DIAP1.
FIG. 1. Caspase-mediated DIAP1 cleavage occurs in apoptotic
S2 cells following UV light irradiation. A, Drosophila S2 cells were
UV light-irradiated, and lysates were collected at the times shown after
irradiation and analyzed by Western blotting with anti-DIAP1 mono-
clonal antibody. The lanes labeled C contain lysates from control, un-
treated cells. B–D, cells were treated at the time of irradiation with the
proteasome inhibitor MG132 (B), the caspase inhibitor z-VAD-FMK (C),
or both MG132 and z-VAD-FMK (D). The positions of molecular mass
markers are indicated on the left.
FIG. 2. DIAP1 undergoes continuous caspase cleavage in nor-
mal S2 cells. A, S2 cells were treated with either Me2SO as a carrier
control (lane labeled C) or MG132 dissolved in Me2SO and at various
times after addition of the drug, lysates were harvested and subjected
to Western blotting with anti-DIAP1 antibody. B, S2 cells were treated
with dsRNA corresponding to DRONC or DARK for 24 h, and then
MG132 was added to the cells, and lysates were prepared at the times
shown after addition of MG132 and analyzed by Western blotting with
anti-DIAP1 antibody. C, control untreated cells. C, S2 cells were treated
with dsRNA corresponding to DIAP1 and at the times shown cell
lysates were harvested and immunoprecipitated with anti-DRONC an-
tisera and immunoprecipitated DIAP1 protein was detected by Western
analysis. Asterisks mark the position of the heavy and light immuno-
globulin chains used for the immunoprecipitation (IP). The migration of
full-length (FL) DIAP1 and cleaved DIAP1 are indicated at the right.
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To determine the DRONC cleavage site, we examined the
amino acid sequence of DIAP1 for potential cleavage sites that
would result in a C-terminal cleavage product of 27 kDa.
DRONC is unusual among caspases in that it has been shown
to cleave after both glutamate and aspartate residues (32).
Residues Asp-201 and Glu-205 are both in the spacer region of
DIAP1 between the first and second BIRs and, if cleaved, would
result in a C-terminal fragment of approximately the correct
size. We therefore mutated DIAP1 at these residues by chang-
ing these residues to alanines (E205A and D201A) and ex-
pressed them in bacteria to generate recombinant proteins.
After incubation with increasing concentrations of active
DRONC, samples were immunoblotted using anti-DIAP1 anti-
body, and it was observed that both wild type DIAP1 and the
D201A mutant were cleaved by DRONC into two fragments of
50 and 27 kDa (Fig. 3, A and B). In contrast DRONC cleavage
of the E205A mutant was greatly inhibited (Fig. 3C) and was
only observed when incubated with high concentrations of
DRONC. In addition, the E205A/D201A double mutant showed
little to no cleavage even when incubated with high concentra-
tions of DRONC (Fig. 3D), suggesting that the cleavage prod-
ucts observed with the E205A mutant may have been because
of DRONC cleavage at amino acid Asp-201 and/or cleavage at
other less efficient sites. These results indicate that DRONC
cleaves DIAP1 after amino acid Glu-205 and support a recent
publication that reported the same DRONC cleavage site in
vitro (28).
Glu-205 Mutations Inhibit DRONC Binding in Vitro and
Have Reduced Ability to Inhibit Apoptosis—Recent reports
have shown that DIAP1 is also cleaved by the effector caspase
DrICE at amino acid Asp-20 (27, 28). These reports found that
DrICE cleavage of DIAP1 was required for DrICE binding to
DIAP1 and was important for DIAP1 activity. We therefore
hypothesized that DRONC cleavage of DIAP1 may also play a
role in DRONC binding to DIAP1 and be important for DIAP1
activity. To examine the effects of DIAP1 cleavage on DRONC
binding, various purified DIAP1 mutant proteins were incu-
bated with bacterially expressed DRONC that was either fully
processed (active) or a catalytically inactive DRONC mutant
(C318S) that was full-length. Immunoprecipitation of these
samples indicated that wild type DIAP1, and the D201A mu-
tant bound both processed and full-length DRONC (Fig. 4).
DIAP1 was cleaved by active DRONC and both the N- and
C-terminal fragments of DIAP1 were immunoprecipitated, in-
dicating that the both fragments remained bound to DRONC
following cleavage, at least stably enough to be immunoprecipi-
tated. However the E205A mutant bound only full-length
DRONC and was unable to bind active DRONC (Fig. 4), indi-
cating that presence of an intact cleavage site in DIAP1 is
important for this processed form of DRONC to bind DIAP1.
To investigate the role of DRONC cleavage on the anti-
apoptotic activity of DIAP1, untagged wild type DIAP1, N-
DIAP1 (amino acids 1–205 of DIAP1), C-DIAP1 (amino acids
205–438 of DIAP1 with an initiating methionine), or the single,
double, and triple combinations of the point mutants D20A,
D201A, and E205A were transiently expressed in S2 cells, and
the cells were co-transfected with a construct expressing
Reaper to induce apoptosis (Fig. 5A). As previously reported
(27), mutation of Asp-20 reduced the ability of DIAP1 to protect
against Reaper-induced death by 50%. In addition, mutation
of residue Glu-205 also reduced the anti-apoptotic function of
DIAP1 against Reaper-induced death (Fig. 5A), although not to
the same degree as mutation of Asp-20. Mutation of Asp-201
had no effect on Reaper-induced apoptosis. Interestingly, al-
though the D20A/D201A mutant behaved similarly to the
D20A mutant, the ability of the D20A/E205A double mutant to
inhibit Reaper-induced death was similar to the E205A mu-
tant. This would fit with an interaction between DIAP1 and
DRONC being epistatic to the interaction between DIAP1 and
DrICE. Expression of C-DIAP1 also had a reduced ability to
inhibit Reaper-induced death, whereas expression of N-DIAP1
had no anti-apoptotic activity, and expression of both C- and
N-DIAP1 together was similar to expression of C-DIAP1 alone.
When a different death stimulus, UV light irradiation, was
used, mutation of Asp-20 and/or Glu-205 had less of an inhib-
itory effect on anti-apoptotic function than against Reaper.
However both mutants still had slightly reduced anti-apoptotic
function compared with wild type or the Asp-201 mutant (Fig.
5B). As seen with Reaper overexpression, C-DIAP1 protected
less well than any of the point mutants, whereas expression of
N-DIAP1 did not protect at all.
All of the mutant proteins were expressed at levels equal to
or higher than the wild type DIAP1 construct, with the excep-
tion of C-DIAP1 (Fig. 5C). Expression of C-DIAP1 did, however,
provide some protection compared with the negative control,
indicating that it was expressed, but the protein was probably
highly unstable because of the presence of the RING domain.
This is consistent with the observation that the 27-kDa DIAP1
cleavage product, which is essentially the same as C-DIAP1,
was not observed unless cells were treated with proteasome
inhibitor (Figs. 1 and 2).
DISCUSSION
In previous studies we have shown that addition of MG132 to
normal living S2 cells caused the over-accumulation of a pro-
cessed form of DRONC, whereas full-length DRONC levels
remained unaffected (17). This suggested that DRONC was
being continuously processed and once processed, targeted for
degradation by the proteasome. In this report we found that
MG132 treatment of normal living S2 cells also caused the
over-accumulation and modification of a C-terminal cleavage
fragment of DIAP1. We also observed that similar to full-length
DRONC, full-length DIAP1 protein levels were unaffected by
FIG. 3. DIAP1 is cleaved in vitro by DRONC at position Glu-
205. GST-tagged wild type (WT) DIAP1 or DIAP1 with point mutations
at positions 201 (D201A) or 205 (E205A) or both positions was incu-
bated with increasing concentrations of recombinant His-tagged
DRONC, and cleavage of DIAP1 was monitored by Western blotting.
Molecular mass markers are indicated at the left.
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MG132 treatment. We were able to conclude that DRONC
directly cleaves DIAP1 in S2 cells based on several pieces of
evidence. 1) Reducing the levels of either DRONC or DARK by
RNAi inhibited the production of the 27-kDa fragment of
DIAP1; 2) endogenous DRONC interacted with both full-length
DIAP1 and the C-terminal DIAP1 cleavage fragment; and 3)
experiments using recombinant, purified proteins revealed
that DRONC cleaved DIAP1 and produced a cleavage product
similar in size to that seen in S2 cells. It is unclear why this
27-kDa cleavage product has not been reported by other groups
who have examined DIAP1 cleavage in S2 cells (27, 29), but it
may be because of the antibody we used to detect DIAP1, which
was different from that used by the other groups.
Our data, including that presented here and in previous
publications (17, 18), point to a model wherein DRONC, DARK,
DIAP1, and DrICE exist in an apoptosome-like complex and
autoactivation of DRONC occurs spontaneously in a DARK-de-
pendent fashion, resulting in cleavage at residue Glu-352 of
DRONC, separating the large and small subunits (18). In this
model, activated DRONC then cleaves DIAP1 at Glu-205 and is
subsequently ubiquitinated by DIAP1 and degraded. The C-
terminal cleavage product of DIAP1, containing the RING do-
main, is also ubiquitinated and degraded. These events appear
to occur continuously in unstimulated S2 cells. Interruption of
the DIAP1-DRONC interaction, whether by Reaper, Hid, or
Grim binding or by a decrease in DIAP1 levels, results in the
accumulation of activated DRONC and subsequent cleavage
and activation of DrICE. Cleavage of DIAP1 by DrICE at po-
sition Asp-20 then occurs (27), and this cleavage event has been
reported to be required for inhibition of DrICE by DIAP1 (28).
The observation that the D20A/E205A double mutant protected
at a level similar to the E205A mutant (Fig. 5A) supports the
FIG. 4. An intact cleavage site is re-
quired for interaction of DIAP1 and
fully processed DRONC. Recombinant
active, processed DRONC or catalytically
inactive, unprocessed DRONC was incu-
bated with the indicated DIAP1 recombi-
nant proteins and was then immunopre-
cipitated using anti-DRONC antibody.
Immunoprecipitated (IP) proteins were
then Western blotted using anti-DIAP1
antibody. FL, full-length.
FIG. 5. Mutation of the DRONC cleavage site affects the ability of DIAP1 to inhibit apoptosis. A, S2 cells were transfected with a
plasmid expressing eGFP alone (Negative control) or co-transfected with plasmids expressing eGFP, the indicated DIAP1 mutant, and Reaper, and
the viability of the transfected cells was determined 48 h later. B, S2 cells were transfected with a plasmid expressing eGFP alone (negative control)
or co-transfected with plasmids expressing eGFP and the indicated DIAP1 mutant. Twenty hours after transfection cells were UV light-irradiated,
and transfected cell viability was determined 24 h later. C, lysates from S2 cells transfected with eGFP alone (negative control), or the indicated
DIAP1 constructs were analyzed by Western blotting using anti-DIAP1 antibody. WT, wild type.
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conclusion that cleavage at Glu-205 occurs prior to that at
Asp-20, as does the observation that DRONC activation occurs
prior to DrICE activation following a death signal (17).
The interaction between DIAP1 and either full-length
DRONC or Pr1 DRONC, the predominant active form of
DRONC in apoptotic cells (DRONC cleaved only at position
Glu-352 between the large and small subunits) (18), appears to
be different from the interaction of DIAP1 with fully active
DRONC that is expressed in bacteria, which is cleaved at
Glu-352 and also at an unidentified residue lying between the
prodomain and the large subunit (18). The interaction between
DIAP1 and full-length DRONC has been shown to involve BIR2
of DIAP1 and amino acids 114–125 of DRONC (33), but this
sequence is probably not present in bacterially expressed active
DRONC due to cleavage during processing (18). The interaction
between bacterially expressed active DRONC and DIAP1 ap-
pears instead to involve the active site of DRONC and Glu-205
of DIAP1, because fully processed DRONC requires an intact
cleavage site at position Glu-205 for interaction with DIAP1,
whereas full-length DRONC does not (Fig. 4).
Mutation of either of the caspase cleavage sites in DIAP1
(Asp-20 or Glu-205) had a negative effect on the ability of
DIAP1 to protect cells against Reaper-induced apoptosis; how-
ever, in both cases the mutant proteins still retained signifi-
cant anti-apoptotic function. Similar results were previously
reported for the D20A mutant against Reaper (27). These ob-
servations suggest that although caspase cleavage of DIAP1
may normally be important for its anti-apoptotic function, it is
not absolutely essential. It is likely that the effect of mutating
the cleavage site is being masked by overexpression of the
mutant proteins in these experiments. The levels of overex-
pressed DIAP1 were much higher than the levels of endoge-
nous DIAP1 in this system, which was not even detected with
the amount of lysate used for analysis (Fig. 5C, compare the
first two lanes). The effect of mutating Asp-20 or Glu-205 was
even less on UV light-induced apoptosis. This could be because
Reaper-induced apoptosis and UV light-induced apoptosis in-
volve different pathways, or because Reaper-induced apoptosis
may be a stronger death stimulus than the dose of UV light
used in these experiments.
It was recently reported that BIR1 of DIAP1 is necessary and
sufficient for inhibition of DrICE enzyme activity in vitro (28).
However in our experiments expression of N-DIAP1, contain-
ing amino acids 1–205 and including all of BIR1, had no ability
to protect S2 cells against apoptosis stimulated by either
Reaper or UV light, even though the truncated protein was
expressed at high levels (Fig. 5). Because RNAi of DrICE is
highly effective at inhibiting apoptosis in S2 cells (18), this
result indicates that merely inhibiting the catalytic activity of
DrICE is not sufficient to prevent apoptosis and points to the
importance of the RING domain in the anti-death function of
DIAP1, as reported previously (27).
DIAP1 has a pivotal role in regulating apoptosis in Drosoph-
ila, and it is a critical determinant for whether cells die or live.
Although mutating the DRONC cleavage site in DIAP1 did not
completely eliminate DIAP1 function when DIAP1 was overex-
pressed, the interactions between DIAP1 and DRONC are
clearly important for regulating apoptosis, and this study has
reported and characterized a novel feature of that interaction.
Future studies may reveal a more significant role for this
cleavage event when the proteins are expressed at physiologi-
cally relevant levels.
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